Core Insights - Fennec Pharmaceuticals Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:00 p.m. ET, available via webcast [1][2] Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity in cancer patients [3] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3] Licensing and Commercialization - In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently commercially available in the U.K. and Germany [4] Regulatory Status and Market Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., while PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents protecting PEDMARK until 2039 in both the U.S. and internationally [5]

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company’s previously announced underwritten public offering in the United States and concurrent private ...

Core Points - Fennec Pharmaceuticals Inc. has closed a non-brokered offering of common shares in Canada at a price of US$7.50 per share, raising aggregate gross proceeds of US$5,025,000 [1][2] Group 1: Offering Details - The offering was made to prospective purchasers in Canada (excluding Quebec) under the listed issuer financing exemption, and the common shares are not subject to a hold period under Canadian securities laws [2][4] - The offering document related to this transaction can be accessed on the Company's profile at www.sedarplus.com and www.fennecpharma.com [3] Group 2: Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with its primary product being PEDMARK, which received FDA approval in September 2022 and European Commission approval in June 2023 [6][8] - PEDMARQSI, the brand name for PEDMARK in the U.K., received approval in October 2023, and the product is now commercially available in the U.K. and Germany following an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. [7][8] Group 3: Regulatory and Market Position - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [8] - Fennec holds patents for PEDMARK that extend until 2039 in both the U.S. and internationally, enhancing its competitive position in the market [8]

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters’ option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec’s total gross proceeds from the offering (before deducting the underw ...

Core Viewpoint - Fennec Pharmaceuticals Inc. is initiating a non-brokered offering of common shares in Canada at a price of US$7.50 per share, aiming for gross proceeds of up to US$5,025,000, with the offering expected to close on November 17, 2025, subject to customary closing conditions [1][2]. Offering Details - The offering targets prospective purchasers in Canada (excluding Quebec) under the listed issuer financing exemption, and the shares will not be subject to a hold period under Canadian securities laws [2][4]. - There are no guarantees regarding the completion of the offering or the total gross proceeds raised [2]. Company Background - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its product PEDMARK approved by the FDA in September 2022 and by the European Commission in June 2023 [6][8]. - The company has an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand, with the product already available in the U.K. and Germany [7]. Regulatory and Market Position - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has Pediatric Use Marketing Authorization in Europe, providing significant market protection [8]. - Fennec holds patents for PEDMARK that extend until 2039 in both the U.S. and internationally, enhancing its competitive position in the market [8].

Core Viewpoint - Fennec Pharmaceuticals Inc. has announced a public offering of 4,666,667 common shares priced at $7.50 per share, aiming to raise approximately $35 million in gross proceeds before expenses [1][2] Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 700,000 common shares under the same terms [1] - The expected closing date for the offering is November 17, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used to repurchase and redeem certain indebtedness, with any remaining funds allocated for working capital and general corporate purposes [2] Group 3: Company Background - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, with its product PEDMARK approved by the FDA in September 2022 and by the European Commission in June 2023 [5][6] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand [6] - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [7]

Core Viewpoint - Fennec Pharmaceuticals Inc. is initiating an underwritten public offering of its common shares, with plans to use the proceeds for debt repayment and general corporate purposes [1][2]. Group 1: Offering Details - The company intends to offer common shares and grant underwriters a 30-day option to purchase an additional 15% of the shares sold in the offering [1]. - The offering is being conducted under a registration statement that has been declared effective by the SEC, with a preliminary prospectus supplement to be filed [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to repurchase certain indebtedness, with any remaining funds allocated for working capital and general corporate purposes [2]. Group 3: Company Background - Fennec Pharmaceuticals focuses on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, primarily through its product PEDMARK, which has received various regulatory approvals [5][6]. - PEDMARK has Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing significant market protection [7].

Core Insights - Fennec Pharmaceuticals reported a record net product sales of $12.5 million for Q3 2025, representing a 79% year-over-year growth, marking the strongest quarter in the company's history [1][8] - The company achieved positive cash flow from operations, with cash and cash equivalents increasing to $22 million as of September 30, 2025 [1][8] - The preliminary results of the clinical trial STS-J01 in Japan are expected in Q4 2025, which could lead to potential registration and partnership opportunities for PEDMARK if results are favorable [1][7] Financial Performance - Net product sales for Q3 2025 were approximately $12.5 million, up from $7.0 million in Q3 2024, indicating significant growth [8][10] - Selling and marketing expenses increased to $5.2 million in Q3 2025 from $4.4 million in Q2 2025 and $4.6 million in Q3 2024 [8] - General and administrative expenses decreased slightly to $6.8 million in Q3 2025 from $7.0 million in Q2 2025 [8] Business Developments - The adoption of PEDMARK has accelerated within key oncology provider networks, reflecting growing confidence in its clinical value [7] - The company is engaged with key opinion leaders and has multiple investigator-initiated studies under review, which are expected to strengthen its clinical and commercial foundation [7] - Fennec's strategy to enhance its commercial organization and drive broader adoption of PEDMARK is showing tangible results [2][7] Upcoming Events - Fennec Pharmaceuticals will host one-on-one investor meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 [4]

Core Insights - Fennec Pharmaceuticals reported total net revenues of $9.7 million for Q2 2025, reflecting a 33% increase compared to the same quarter in 2024, driven by growth in large community practices and academic centers [1][3][9] - The company has seen a successful uptake of its product PEDMARQSI in the UK and Germany, with plans for additional EU launches [1][3] - The management anticipates results from a clinical trial in Japan (STS-J01) in the second half of 2025, which may lead to registration and potential licensing opportunities [1][3] Financial Performance - Net product sales for Q2 2025 were approximately $9.7 million, up from $7.3 million in Q2 2024, attributed to growth in the adolescent and young adult (AYA) population [9][11] - Selling and marketing expenses decreased to $4.4 million in Q2 2025 from $4.6 million in Q2 2024, while general and administrative expenses increased slightly to $7.0 million from $6.9 million [9][11] - The company reported a net loss of $3.2 million for Q2 2025, compared to a net loss of $5.6 million in Q2 2024 [11] Business Highlights - Fennec's segmentation model and data-driven targeting have led to significant growth in both new and repeat customers, particularly in large community and academic practices [6] - A large national oncology group has added PEDMARK to its formulary for patients under 40, indicating growing recognition of the need to protect younger patients from cisplatin-induced hearing loss [6] - The NCODA PQI issued for PEDMARK aims to provide clinical data and guidance for healthcare professionals managing patients on cancer therapies [6] Upcoming Events - Fennec will ring the NASDAQ closing bell on September 5, 2025, alongside PEDMARK patients and their families [10] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [10] Product Information - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients [15][19] - The product has received Orphan Drug Exclusivity in the U.S. and is commercially available in the U.K. and Germany under the brand name PEDMARQSI [28][30]

Core Insights - Fennec Pharmaceuticals reported first quarter 2025 total net revenues of $8.8 million, representing an 18% increase year over year from $7.4 million in the first quarter of 2024 [1][5][10] - The company has successfully launched PEDMARQSI in Germany and the United Kingdom, enhancing access to its product for cancer patients at risk of hearing loss [1][6][29] - The revamped Fennec HEARS™ patient support program aims to improve the experience for adolescent and young adult cancer patients [2][6] Financial Results - Net product sales for the first quarter of 2025 were approximately $8.8 million, up from $7.4 million in the same period last year [5][10] - Total revenue for the first quarter was $8.8 million, with no licensing revenue recorded compared to $17.96 million in the first quarter of 2024 [10] - Operating expenses totaled $9.56 million, down from $11.63 million in the previous year, with selling and marketing expenses decreasing to $2.95 million from $5.21 million [11][10] Business Highlights - The company has strengthened its segmentation model and data-driven target lists, leading to the addition of multiple new accounts across academic and community providers [6][7] - The commercial launch of PEDMARQSI in Europe marks a significant step in expanding access to the product [6][29] - Fennec will participate in the ASCO 2025 Annual Meeting and other investor conferences, indicating ongoing engagement with the medical and investment communities [6][4] Upcoming Events - Fennec will host a conference call on May 13, 2025, at 8:30 a.m. ET to discuss its financial results and business updates [1][8] - The Annual General Meeting is scheduled for June 3, 2025, in New York, providing an opportunity for shareholder engagement [6][4]